Crossmark

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway

Crossref DOI link: https://doi.org/10.1007/s40273-017-0604-3

Published Online: 2018-02-02

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wisløff, Torbjørn https://orcid.org/0000-0002-7539-082X
White, Richard

Dalgard, Olav

Amundsen, Ellen J.

Meijerink, Hinta

Løvlie, Astrid Louise

Kløvstad, Hilde
License Information

Text and Data Mining valid from 2018-02-02
More Information

Article History

First Online: 2 February 2018

Compliance with Ethical Standards

:

: No direct funding was provided for the work performed. The research was undertaken as part of regular work at the Norwegian Institute of Public Health, University of Oslo and Akershus University Hospital. The study was initiated by the researchers included as authors. No other persons had any influence on the work performed.

: Olav Dalgard has received consulting fees and/or research grants from Abbvie, Merck, and Gilead. Torbjørn Wisløff, Richard White, Ellen J. Amundsen, Hinta Meijerink, Astrid Løvlie and Hilde Kløvstad declare no conflicts of interest.